Aegis Capital Maintains Inovio (INO) at Hold; Still Sees Neutral Risk/Reward Following Q3 Numbers

November 13, 2013 11:09 AM

Aegis Capital affirms its Hold rating and $2.50 price target on Inovio Pharmaceuticals, Inc. (AMEX: INO) following Q3 results issued ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found